Share
Services
FDA has extended regulatory discretion on sodium chloride infusion solutions (until May 31) and trace elements (until June 30,) but has discontinued discretion to import Glycophos (Dec. 31, 2014). Accordingly, Fresenius Kabi expects lower 2015 sales from products imported under regulatory discretion. Fresenius Kabi expects 2015 IV generic product launches to be backloaded.
Moxifloxacin injection further expands the Fresenius Kabi anti-infective portfolio. It is available in the company's proprietary Freeflex® bag.
Cisatracurium Besylate Injection, a neuromuscular blocker, further expands Fresenius Kabi's anesthesia portfolio. Now available in three presentations.
Glucagon injection expands Fresenius Kabi's U.S. critical care portfolio and is sold in 10-packs of 1mg vials.
Filling of glass bottles with liquid pharmaceuticals at the Fresenius Kabi plant in Melrose Park, USA.
Filling of glass bottles with liquid pharmaceuticals at the Fresenius Kabi plant in Quy Nhon, Vietnam.
Industrial production of infusion solutions at Fresenius Kabi's plant in Friedberg, Germany.
Filling of glass ampoules with liquid pharmaceuticals at Fresenius Kabi.
A nurse prepares an intravenously administered (I.V.) drug. Fresenius Kabi is a leading supplier of I.V. generic drugs. Seen in the background are Agilia series infusion pumps for the administration of I.V. drugs.
In Friedberg, Germany, Fresenius Kabi operates a state of the art production facility for infusion solutions.
